• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Genentech

Genentech

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. FDA Grants Genentech ’s Alecensa Priority Review for Initial Treatment of People with ALK-Positive Lung Cancer

    FDA Grants Genentech ’s Alecensa Priority Review for Initial Treatment of People with ALK-Positive Lung Cancer

  2. Positive Phase III Results of Genentech ’s Actemra (Tocilizumab) for the Treatment of Giant Cell Arteritis Published in New England Journal of Medicine

    Positive Phase III Results of Genentech ’s Actemra (Tocilizumab) for the Treatment of Giant Cell Arteritis Published in New England Journal of Medicine

  3. Global Biorefinery technologies Market to Reach $980 Billion by 2025 - Analysis By Feedstock, Products, Raw Material, Technology, Application & Geography - Research and Markets

    Global Biorefinery technologies Market to Reach $980 Billion by 2025 - Analysis By Feedstock, Products, Raw Material, Technology, Application & Geography - Research and Markets

12345

©2017 Morningstar Advisor. All right reserved.